search
Back to results

Efficacy and Safety of TAK-875 in Combination With Sitagliptin in Participants With Type 2 Diabetes Mellitus

Primary Purpose

Diabetes Mellitus, Type 2

Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Placebo
TAK-875
TAK-875
Sitagliptin
TAK-875 and Sitagliptin
TAK-875 and Sitagliptin
Sponsored by
Takeda
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diabetes Mellitus, Type 2 focused on measuring Drug Therapy

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. In the opinion of the investigator, the participant is capable of understanding and complying with protocol requirements.
  2. The participant or, when applicable, the participant's legally acceptable representative signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures.
  3. The participant has either:

    • A historical diagnosis of Type 2 Diabetes (T2DM) without the chronic use (defined as >7 days) of anti-diabetic therapy within 8 weeks prior to Screening, and with at least an 8-week documented history of a diet and exercise plan at Screening OR,
    • A historical diagnosis of T2DM and stable on at least 1500 mg per day (or maximum tolerated dose) of metformin as monotherapy for at least 8 weeks at Screening. Participants on a stable dose of metformin who enter the study will continue on the same dose of metformin throughout the duration of the study.
  4. The participant is a man or woman and aged 18 to 80 years, inclusive.
  5. The participant's body mass index (BMI) (kg/m2) at Screening is ≥23 and ≤45.
  6. The participant has an glycosylated hemoglobin (HbA1c) level at Screening between 7.5% and 10.0%, inclusive, if on metformin and between 7.5% to 10.9%, inclusive, if treated with diet and exercise alone.
  7. The participant has a fasting plasma glucose level <14.4 mmol/L (<260 mg/dL), at Screening.
  8. The participant has a fasting C-peptide concentration ≥0.26 nmol/L (≥0.8 ng/mL) at Screening.
  9. If the participant takes any chronic, non-excluded medications, the dose of these medications must have been stable (no change in dose or drug) for at least 4 weeks prior to Screening.
  10. The participant is able and willing to monitor their glucose levels with a home glucose monitor and consistently record his or her own blood glucose concentrations according to the given instructions.
  11. A male participant who is nonsterilized and sexually active with a female partner of childbearing potential agrees to use adequate contraception from signing of informed consent throughout the duration of the study and for 30 days after last dose.
  12. A female participant of childbearing potential who is sexually active with a nonsterilized male partner agrees to use routinely adequate contraception from signing of informed consent throughout the duration of the study.
  13. A female participant of childbearing potential must have a negative serum human chorionic gonadotropin (HCG) pregnancy test at Screening (Visit 1) and at Placebo Run-in (Visit 2). A negative urine HCG pregnancy test is also required at Randomization (Visit 3), prior to administration of the first dose of double-blind study medication.
  14. The participant's compliance with single-blind study medication during the run-in phase is at least 80% and does not exceed 120% based on tablet counts performed by the study staff.

Exclusion Criteria:

  1. The participant has received any investigational compound within 4 weeks prior to Screening.
  2. The participant has been enrolled in a previous TAK-875 study.
  3. The participant is an immediate family member, study site employee, or is in a dependent relationship with a study site employee who is involved in conduct of this study (eg, spouse, parent, child, sibling) or may consent under duress.
  4. The participant has a history of hypersensitivity or allergies to TAK-875 or sitagliptin, or their excipients.
  5. The participant has a history of drug abuse (defined as any illicit drug use) or a history of alcohol abuse within 2 years prior to the Screening visit.
  6. The participant has a history of cancer that has been in remission for <5 years prior to Screening (a history of basal cell carcinoma or stage 1 squamous cell carcinoma of the skin is allowed).
  7. The participant has systolic blood pressure ≥150 mm Hg or diastolic pressure ≥90 mm Hg at Screening (Visit 1) or Baseline (Visit 3) (as confirmed by repeat measurement 30 minutes after initial measurement).
  8. The participant has a creatine phosphokinase (CPK) level ≥5x the upper limit of normal (ULN) at Screening.
  9. The participant has a hemoglobin level of ≤12 g/dL (120 gm/L) for men and ≤10 g/dL (100 gm/L) for women at Screening.
  10. The participant has ALT and/or AST levels ≥2.5x ULN at Screening.
  11. The participant has a total bilirubin level > ULN at Screening.
  12. The participant has a serum triglyceride concentration ≥4.5 mmol/L (≥400 mg/dL) at Screening.
  13. The participant has an estimated glomerular filtration rate ≤60mL/min using the Modification of Diet in Renal Disease (MDRD) equation at Screening.
  14. The participant has a documented history or concurrent signs of uncontrolled (not euthyroid) thyroid disease (eg, autoimmune thyroid diseases such as Graves disease and Hashimoto thyroiditis or active thyroid nodules).
  15. The participant has a history of pancreatitis.
  16. The participant has a history of laser treatment for proliferative diabetic retinopathy within 6 months prior to Screening.
  17. The participant has a history of gastric bypass surgery or has diabetic gastroparesis that in the investigator's opinion is moderate or severe and hence may impair absorption of study medication.
  18. The participant has had coronary angioplasty, coronary stent placement, coronary bypass surgery, myocardial infarction, unstable angina pectoris, clinically significant abnormal electrocardiogram (ECG), cerebrovascular accident or transient ischemic attack within 6 months prior or at Screening.
  19. The participant has a history of any hemoglobinopathy that may affect determination of HbA1c.
  20. The participant has a positive test result for hepatitis B surface antigen and antibody to hepatitis C virus, and/or has known history of human immunodeficiency virus at Screening.
  21. The participant has donated or received any blood products within 12 weeks prior to Screening.
  22. The participant received medication prior to Screening as listed in the excluded Medications section.
  23. If female, the participant is pregnant or lactating or intending to become pregnant before, during, or within 1 month after participating in this study; or intending to donate an ova during such time period.
  24. If male, the participant intends to donate sperm during the course of this study or for 30 days thereafter.
  25. The participant has any other physical or psychiatric disease or condition that in the judgment of the investigator may affect life expectancy or may make it difficult to successfully manage and follow the participant according to the protocol.

Sites / Locations

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm 6

Arm Type

Placebo Comparator

Experimental

Experimental

Experimental

Experimental

Experimental

Arm Label

Placebo QD

TAK-875 25 mg QD

TAK-875 50 mg QD

Sitagliptin 100 mg QD

TAK-875 25 mg QD + Sitagliptin 100 mg QD

TAK-875 50 mg QD + Sitagliptin 100 mg QD

Arm Description

Outcomes

Primary Outcome Measures

Change from Baseline in Glycosylated Hemoglobin (HbA1c)
The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 12 relative to baseline.

Secondary Outcome Measures

Change from Baseline in Fasting Plasma Glucose
The change between the fasting plasma glucose value collected at week 12 relative to baseline.

Full Information

First Posted
August 10, 2011
Last Updated
March 4, 2016
Sponsor
Takeda
search

1. Study Identification

Unique Protocol Identification Number
NCT01414920
Brief Title
Efficacy and Safety of TAK-875 in Combination With Sitagliptin in Participants With Type 2 Diabetes Mellitus
Official Title
A Phase 2, Randomized, Placebo-Controlled, Factorial, Double-Blind, Double-Dummy, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of 25 mg and 50 mg of TAK-875 in Combination With Sitagliptin 100 mg in Subjects With Type 2 Diabetes Mellitus
Study Type
Interventional

2. Study Status

Record Verification Date
March 2016
Overall Recruitment Status
Completed
Study Start Date
August 2011 (undefined)
Primary Completion Date
August 2012 (Actual)
Study Completion Date
August 2012 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Takeda

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to determine the efficacy and safety of TAK-875, once daily (QD), in combination with sitagliptin QD in participants with type 2 diabetes mellitus (T2DM).
Detailed Description
TAK-875 is being developed at Takeda Global Research and Development, Inc. as an adjunct to diet and exercise to improve glycemic control in patients with T2DM. Sitagliptin is an inhibitor of dipeptidyl peptidase-4 (DPP-4) approved as an adjunct to diet and exercise to improve glycemic control in adults with T2DM. This study will investigate the effects of the combination of TAK-875 with a DDP-4 inhibitor on glycosylated hemoglobin reduction.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Type 2
Keywords
Drug Therapy

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
368 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Placebo QD
Arm Type
Placebo Comparator
Arm Title
TAK-875 25 mg QD
Arm Type
Experimental
Arm Title
TAK-875 50 mg QD
Arm Type
Experimental
Arm Title
Sitagliptin 100 mg QD
Arm Type
Experimental
Arm Title
TAK-875 25 mg QD + Sitagliptin 100 mg QD
Arm Type
Experimental
Arm Title
TAK-875 50 mg QD + Sitagliptin 100 mg QD
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
TAK-875 and sitagliptin placebo-matching tablets, orally, once daily for up to 12 weeks.
Intervention Type
Drug
Intervention Name(s)
TAK-875
Intervention Description
TAK-875 25 mg, tablets, orally, once daily for up to 12 weeks.
Intervention Type
Drug
Intervention Name(s)
TAK-875
Intervention Description
TAK-875 50 mg, tablets, orally, once daily for up to 12 weeks.
Intervention Type
Drug
Intervention Name(s)
Sitagliptin
Other Intervention Name(s)
Januvia
Intervention Description
Sitagliptin 100 mg, tablets, orally, once daily for up to 12 weeks.
Intervention Type
Drug
Intervention Name(s)
TAK-875 and Sitagliptin
Other Intervention Name(s)
Januvia
Intervention Description
TAK-875 25 mg, tablets, orally, once daily and sitagliptin 100 mg tablets, orally, once daily for up to 12 weeks.
Intervention Type
Drug
Intervention Name(s)
TAK-875 and Sitagliptin
Other Intervention Name(s)
Januvia
Intervention Description
TAK-875 50 mg, tablets, orally, once daily and sitagliptin 100 mg tablets, orally, once daily for up to 12 weeks.
Primary Outcome Measure Information:
Title
Change from Baseline in Glycosylated Hemoglobin (HbA1c)
Description
The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 12 relative to baseline.
Time Frame
Baseline and Week 12.
Secondary Outcome Measure Information:
Title
Change from Baseline in Fasting Plasma Glucose
Description
The change between the fasting plasma glucose value collected at week 12 relative to baseline.
Time Frame
Baseline and Week 12.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: In the opinion of the investigator, the participant is capable of understanding and complying with protocol requirements. The participant or, when applicable, the participant's legally acceptable representative signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures. The participant has either: A historical diagnosis of Type 2 Diabetes (T2DM) without the chronic use (defined as >7 days) of anti-diabetic therapy within 8 weeks prior to Screening, and with at least an 8-week documented history of a diet and exercise plan at Screening OR, A historical diagnosis of T2DM and stable on at least 1500 mg per day (or maximum tolerated dose) of metformin as monotherapy for at least 8 weeks at Screening. Participants on a stable dose of metformin who enter the study will continue on the same dose of metformin throughout the duration of the study. The participant is a man or woman and aged 18 to 80 years, inclusive. The participant's body mass index (BMI) (kg/m2) at Screening is ≥23 and ≤45. The participant has an glycosylated hemoglobin (HbA1c) level at Screening between 7.5% and 10.0%, inclusive, if on metformin and between 7.5% to 10.9%, inclusive, if treated with diet and exercise alone. The participant has a fasting plasma glucose level <14.4 mmol/L (<260 mg/dL), at Screening. The participant has a fasting C-peptide concentration ≥0.26 nmol/L (≥0.8 ng/mL) at Screening. If the participant takes any chronic, non-excluded medications, the dose of these medications must have been stable (no change in dose or drug) for at least 4 weeks prior to Screening. The participant is able and willing to monitor their glucose levels with a home glucose monitor and consistently record his or her own blood glucose concentrations according to the given instructions. A male participant who is nonsterilized and sexually active with a female partner of childbearing potential agrees to use adequate contraception from signing of informed consent throughout the duration of the study and for 30 days after last dose. A female participant of childbearing potential who is sexually active with a nonsterilized male partner agrees to use routinely adequate contraception from signing of informed consent throughout the duration of the study. A female participant of childbearing potential must have a negative serum human chorionic gonadotropin (HCG) pregnancy test at Screening (Visit 1) and at Placebo Run-in (Visit 2). A negative urine HCG pregnancy test is also required at Randomization (Visit 3), prior to administration of the first dose of double-blind study medication. The participant's compliance with single-blind study medication during the run-in phase is at least 80% and does not exceed 120% based on tablet counts performed by the study staff. Exclusion Criteria: The participant has received any investigational compound within 4 weeks prior to Screening. The participant has been enrolled in a previous TAK-875 study. The participant is an immediate family member, study site employee, or is in a dependent relationship with a study site employee who is involved in conduct of this study (eg, spouse, parent, child, sibling) or may consent under duress. The participant has a history of hypersensitivity or allergies to TAK-875 or sitagliptin, or their excipients. The participant has a history of drug abuse (defined as any illicit drug use) or a history of alcohol abuse within 2 years prior to the Screening visit. The participant has a history of cancer that has been in remission for <5 years prior to Screening (a history of basal cell carcinoma or stage 1 squamous cell carcinoma of the skin is allowed). The participant has systolic blood pressure ≥150 mm Hg or diastolic pressure ≥90 mm Hg at Screening (Visit 1) or Baseline (Visit 3) (as confirmed by repeat measurement 30 minutes after initial measurement). The participant has a creatine phosphokinase (CPK) level ≥5x the upper limit of normal (ULN) at Screening. The participant has a hemoglobin level of ≤12 g/dL (120 gm/L) for men and ≤10 g/dL (100 gm/L) for women at Screening. The participant has ALT and/or AST levels ≥2.5x ULN at Screening. The participant has a total bilirubin level > ULN at Screening. The participant has a serum triglyceride concentration ≥4.5 mmol/L (≥400 mg/dL) at Screening. The participant has an estimated glomerular filtration rate ≤60mL/min using the Modification of Diet in Renal Disease (MDRD) equation at Screening. The participant has a documented history or concurrent signs of uncontrolled (not euthyroid) thyroid disease (eg, autoimmune thyroid diseases such as Graves disease and Hashimoto thyroiditis or active thyroid nodules). The participant has a history of pancreatitis. The participant has a history of laser treatment for proliferative diabetic retinopathy within 6 months prior to Screening. The participant has a history of gastric bypass surgery or has diabetic gastroparesis that in the investigator's opinion is moderate or severe and hence may impair absorption of study medication. The participant has had coronary angioplasty, coronary stent placement, coronary bypass surgery, myocardial infarction, unstable angina pectoris, clinically significant abnormal electrocardiogram (ECG), cerebrovascular accident or transient ischemic attack within 6 months prior or at Screening. The participant has a history of any hemoglobinopathy that may affect determination of HbA1c. The participant has a positive test result for hepatitis B surface antigen and antibody to hepatitis C virus, and/or has known history of human immunodeficiency virus at Screening. The participant has donated or received any blood products within 12 weeks prior to Screening. The participant received medication prior to Screening as listed in the excluded Medications section. If female, the participant is pregnant or lactating or intending to become pregnant before, during, or within 1 month after participating in this study; or intending to donate an ova during such time period. If male, the participant intends to donate sperm during the course of this study or for 30 days thereafter. The participant has any other physical or psychiatric disease or condition that in the judgment of the investigator may affect life expectancy or may make it difficult to successfully manage and follow the participant according to the protocol.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Sr. Medical Director Clinical Science
Organizational Affiliation
Takeda
Official's Role
Study Director
Facility Information:
City
Birmingham
State/Province
Alabama
Country
United States
City
Brimingham
State/Province
Alabama
Country
United States
City
Chandler
State/Province
Arizona
Country
United States
City
Glendale
State/Province
Arizona
Country
United States
City
Green Valley
State/Province
Arizona
Country
United States
City
Mesa
State/Province
Arizona
Country
United States
City
Tempe
State/Province
Arizona
Country
United States
City
Tucson
State/Province
Arizona
Country
United States
City
Buena Park
State/Province
California
Country
United States
City
Irvine
State/Province
California
Country
United States
City
Norwalk
State/Province
California
Country
United States
City
Paramount
State/Province
California
Country
United States
City
Rancho Cucamonga
State/Province
California
Country
United States
City
San Ramon
State/Province
California
Country
United States
City
Spring Valley
State/Province
California
Country
United States
City
Vista
State/Province
California
Country
United States
City
Walnut Creek
State/Province
California
Country
United States
City
Westlake Village
State/Province
California
Country
United States
City
Colorado Springs
State/Province
Colorado
Country
United States
City
Lakewood
State/Province
Colorado
Country
United States
City
Brandon
State/Province
Florida
Country
United States
City
Clearwater
State/Province
Florida
Country
United States
City
DeLand
State/Province
Florida
Country
United States
City
Hallandale Beach
State/Province
Florida
Country
United States
City
Hialeah
State/Province
Florida
Country
United States
City
Jupiter
State/Province
Florida
Country
United States
City
Longwood
State/Province
Florida
Country
United States
City
Miami Lakes
State/Province
Florida
Country
United States
City
Miami
State/Province
Florida
Country
United States
City
Orlando
State/Province
Florida
Country
United States
City
Pembroke Pines
State/Province
Florida
Country
United States
City
St Petersburg
State/Province
Florida
Country
United States
City
Tampa
State/Province
Florida
Country
United States
City
Atlanta
State/Province
Georgia
Country
United States
City
Roswell
State/Province
Georgia
Country
United States
City
Suwanee
State/Province
Georgia
Country
United States
City
Boise
State/Province
Idaho
Country
United States
City
Chicago
State/Province
Illinois
Country
United States
City
Valparaiso
State/Province
Indiana
Country
United States
City
Crestview Hills
State/Province
Kentucky
Country
United States
City
Lexington
State/Province
Kentucky
Country
United States
City
Louisville
State/Province
Kentucky
Country
United States
City
Bangor
State/Province
Maine
Country
United States
City
Elkridge
State/Province
Maryland
Country
United States
City
Brockton
State/Province
Massachusetts
Country
United States
City
Chelsea
State/Province
Michigan
Country
United States
City
Kalamazoo
State/Province
Michigan
Country
United States
City
Olive Branch
State/Province
Mississippi
Country
United States
City
Berlin
State/Province
New Jersey
Country
United States
City
Margate
State/Province
New Jersey
Country
United States
City
Toms River
State/Province
New Jersey
Country
United States
City
Brooklyn
State/Province
New York
Country
United States
City
Buffalo
State/Province
New York
Country
United States
City
Calabash
State/Province
North Carolina
Country
United States
City
Fuquay-Varina
State/Province
North Carolina
Country
United States
City
Morehead City
State/Province
North Carolina
Country
United States
City
Winston-Salem
State/Province
North Carolina
Country
United States
City
Akron
State/Province
Ohio
Country
United States
City
Cincinnati
State/Province
Ohio
Country
United States
City
Columbus
State/Province
Ohio
Country
United States
City
Lyndhurst
State/Province
Ohio
Country
United States
City
Marion
State/Province
Ohio
Country
United States
City
Willoughby Hills
State/Province
Ohio
Country
United States
City
Oklahoma City
State/Province
Oklahoma
Country
United States
City
Portland
State/Province
Oregon
Country
United States
City
Broomall
State/Province
Pennsylvania
Country
United States
City
Feasterville
State/Province
Pennsylvania
Country
United States
City
Fleetwood
State/Province
Pennsylvania
Country
United States
City
Cranston
State/Province
Rhode Island
Country
United States
City
Chattanooga
State/Province
Tennessee
Country
United States
City
Crossville
State/Province
Tennessee
Country
United States
City
Kingsport
State/Province
Tennessee
Country
United States
City
Nashville
State/Province
Tennessee
Country
United States
City
Dallas
State/Province
Texas
Country
United States
City
Houston
State/Province
Texas
Country
United States
City
Irving
State/Province
Texas
Country
United States
City
North Richland Hills
State/Province
Texas
Country
United States
City
Pearland
State/Province
Texas
Country
United States
City
San Antonio
State/Province
Texas
Country
United States
City
Seattle
State/Province
Washington
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Efficacy and Safety of TAK-875 in Combination With Sitagliptin in Participants With Type 2 Diabetes Mellitus

We'll reach out to this number within 24 hrs